<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02514967</url>
  </required_header>
  <id_info>
    <org_study_id>AN-SLE3343</org_study_id>
    <nct_id>NCT02514967</nct_id>
  </id_info>
  <brief_title>CHABLIS7.5: A Study of the Efficacy and Safety of Subcutaneous Blisibimod in Subjects With Systemic Lupus Erythematosus With or Without Nephritis</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Blisibimod Administration in Subjects With Systemic Lupus Erythematosus With or Without Nephritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Anthera Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Anthera Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the clinical efficacy of blisibimod as measured by a
      composite responder index in subjects who, despite corticosteroid use, continue to have
      seropositive, clinically-active Systemic Lupus Erythematosus (SLE) as defined by
      SELENA-SLEDAI score ≥10, and positive for anti-double stranded DNA and low complement (C3 or
      C4).
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Study halted prematurely and will not resume. Subjects were seen until February 2017
  </why_stopped>
  <start_date type="Actual">June 2016</start_date>
  <completion_date type="Actual">February 28, 2017</completion_date>
  <primary_completion_date type="Actual">November 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of responders to the SRI-6 composite responder index</measure>
    <time_frame>52 Weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to first severe SLE flare</measure>
    <time_frame>Baseline through 52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the number of actively tender or swollen joints and in mucocutaneous disease activity</measure>
    <time_frame>52 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in proteinuria from baseline</measure>
    <time_frame>Week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects able to reduce oral steroid dose to ≤ 7.5 mg</measure>
    <time_frame>Baseline through 52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with improved patient-reported outcomes</measure>
    <time_frame>Week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to treatment failure</measure>
    <time_frame>Through week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in B cell counts, anti-dsDNA, C3, C4</measure>
    <time_frame>Through week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of adverse events</measure>
    <time_frame>Through week 52</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Occurrence of renal flare in subjects with renal manifestations at baseline</measure>
    <time_frame>52 Weeks</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">3</enrollment>
  <condition>Systemic Lupus Erythematosus</condition>
  <arm_group>
    <arm_group_label>Blisibimod</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Blisibimod</intervention_name>
    <description>Administered via subcutaneous injection once per week</description>
    <arm_group_label>Blisibimod</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Administered via subcutaneous injection once per week</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Fulfill at least 4 diagnostic criteria for SLE defined by American College of
             Rheumatology

          -  Active SLE disease as defined by SELENA-SLEDAI score ≥10 despite on-going stable
             corticosteroid therapy

          -  Positive for anti-double stranded DNA (anti-dsDNA) and low complement

          -  Subjects with stable nephritis may be enrolled

          -  18 years of age or older

        Exclusion Criteria:

          -  Severe active central nervous system lupus

          -  Malignancy within past 5 years

          -  Known to be positive for HIV and/or positive at the screening visit for hepatitis B,
             or hepatitis C

          -  Comorbidities that would interfere with evaluations of study drug effect

          -  Active infection requiring hospitalization or treatment with parenteral antibiotics
             within the past 60 days or history of repeated herpetic viral infections

          -  History of active tuberculosis or a history of tuberculosis infection

          -  Pregnant or nursing
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Investigator Site 004</name>
      <address>
        <city>Tbilisi</city>
        <zip>0102</zip>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site 001</name>
      <address>
        <city>Tbilisi</city>
        <zip>0179</zip>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site 002</name>
      <address>
        <city>Tbilisi</city>
        <zip>0186</zip>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Georgia</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 31, 2015</study_first_submitted>
  <study_first_submitted_qc>July 31, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 4, 2015</study_first_posted>
  <last_update_submitted>May 19, 2017</last_update_submitted>
  <last_update_submitted_qc>May 19, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 23, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>SLE</keyword>
  <keyword>Lupus</keyword>
  <keyword>Lupus Erythematosus, Systemic</keyword>
  <keyword>Autoimmune Diseases</keyword>
  <keyword>A-623</keyword>
  <keyword>Blisibimod</keyword>
  <keyword>Nephritis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lupus Erythematosus, Systemic</mesh_term>
    <mesh_term>Nephritis</mesh_term>
  </condition_browse>
  <pending_results>
    <submitted>April 10, 2018</submitted>
    <returned>May 9, 2018</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

